Compare DexCom, Inc. (DXCM) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Under Armour Inc Class A — how do they compare? DexCom, Inc. trades at $90.66 (market cap $33.79B), while Under Armour Inc Class A trades at $5.17 (market cap $2.26B). The key difference: DexCom, Inc. is far larger — about 15× Under Armour Inc Class A's market cap, and DexCom, Inc. is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| DXCM | UA | |
|---|---|---|
Market Cap | $33.79B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.80 | $7.88 |
52-Week Low | $54.84 | $3.96 |
Enterprise Value | $33.24B | $3.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Under Armour (UA) is trading at $5.12, down 9.78% with bearish technical signals despite some oversold RSI readings. The company faces significant fundamental challenges with negative net income margins (-9.99%) and declining revenue trends from $5.16B in 2025 to $4.9B in 2026. Recent Q1 2027 results showed a revenue decline of 3% to $1.1B, prompting management to lower full-year revenue guidance amid softer consumer demand in key markets.
The outlook remains challenging with persistent profitability issues and negative cash flow trends. While analyst sentiment shows mixed ratings (38.81% Buy, 49.25% Hold), the stock trades at attractive valuation multiples (P/S 0.45) but faces execution risks in its turnaround strategy. Key risks include competitive pressures, inventory management challenges, and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
